3  Commercial 419 20.9 3,190 24.6  Self-pay 40 2.0 145 1.1  Excessive PRN1371 in vitro alcohol consumption (n, %) 8 0.4 32 0.2 Mean Charlson Comorbidity Index (SD) 2.3 1.1 2.0 1.1  0 217 10.8 2,015 15.5  1 263 13.1 2,545 19.6  2 254 12.7 2,356 18.2  3+ 1,269 63.4 6,060 46.7  Oral corticosteroid (n, %) 327 16.3 1,870 14.4  Rheumatoid arthritis (n, %) 50 2.5 575 4.4 Fall history (n, %) 812 40.5 1,445 11.1 Aortic atherosclerosis (n, %) 41 2.0 151 1.2 Chemotherapy (n, %) 669 33.4 4,400 33.9 Diabetes (n, %) 657 32.8 2,844 21.9 Thyroid replacement therapy (n, %) 524 26.2 3,329 25.7 Thyroid disease (n, %) 842 42.0 5,201 40.1 Furosemide therapy (n, %) 695 34.7 2,693 20.8 Malnutrition (n,

%) 291 14.5 1,393 10.7 SD standard deviation, BMD bone mineral density, ICD-9 International Classification of Diseases 9, BMI body mass index Only 188 (9.4%) of the patients in the FRAC group were prescribed find more treatment in the first 90 days post-index date, while 5,395 (41.6%) patients in the ICD-9-BMD group were treated during this same time period (Table 3). For the ICD-9-BMD patients, 45.9% had been prescribed treatment within 180 days while 49.3% had been prescribed treatment within 365 days. Table 3 Frequency of patients treated at 90, 180, and 365 days after index date Number of days from index date Fracture

(n = 2,003) Low BMD or ICD-9 (n = 12,976) n % n % 90 days 188 9.4 5,395 41.6 180 days 268 13.4 5,954 45.9 365 days 371 18.5 6,395 49.3 BMD bone mineral density, ICD-9 International Classification of Diseases In Table 4, results from the logistic regressions are presented for patients in the FRAC group. Baseline results for which treatment was defined as a prescription in the first 90 days following fracture are presented along with alternative Mannose-binding protein-associated serine protease treatment definitions of 180 and 365 days. Individuals between the ages of 65 and 74 were significantly more likely

to get treatment (OR = 1.77, p = 0.009) compared with patients between 50 and 64. A low BMD T-score (≤−2.5) after fracture date was significantly associated with increased likelihood of receiving treatment (OR = 4.90, p < 0.001). Obese patients were less likely to receive treatment than underweight or normal weight patients (OR = 0.53, p = 0.03), and those taking an oral corticosteroid were more likely to receive treatment (OR = 1.67, p = 0.01). The effects of covariates on the likelihood of bisphosphonate treatment were similar using treatment windows of 180 and 365 days post-index date; however, more odds ratios reached statistical significance as the number of treated patients increased. Table 4 Logistic regression for osteoporosis treatment—patients with fracture   Number of days from index date for treatment definition 90 days 180 days 365 days Odds ratio P value Odds ratio P value Odds ratio P value Age  50–64 (ref)              65–74 1.764 0.009 1.784 0.002 1.780 <0.001  75+ 1.469 0.